(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Clones of Stumpy, Washington D.C.'s beloved cherry blossom tree, have flowered for the first time - 25 Cell phones of the Year
- 3'Wow!' The eye surgery marathon that restored sight for some South Africans
- 46 Web-based Staple Help You Can Trust
- 5Hundreds of Gazans evacuated from Strip for medical treatment - COGAT
- No red, no long shorts: The fashion rules Joe Burrows lives by
- South Carolina confirms 124 new measles cases as outbreak on the Arizona-Utah line grows
- Gulf countries continue to face Iran attacks as criticial energy infrastructure at risk
- Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
- Record-breaking 'space laser' erupts from merging galaxies 8 billion light-years away
- The Most Astonishing Arising Advances to Watch
- Figuring out the Business venture Code: The Response to Building an Effective Startup
- African nations push to recognize crimes of colonialism in Algeria
- Bomb blast in packed Nigerian mosque kills five
